APOC3 and hypertriglyceridemia: Recent data from phase II studies confirmed that apoC-III ASO-mediated suppression of apoC-III leads to marked lowering (up to 90 %) of serum apoC-III and up to about an 80 % reduction of VLDL triglyceride levels in patients with familial chylomicron syndrome and with variable types of hypertriglyceridemia [46, 85••, 86••].